Member Info for Bazzaman

https://twitter.com/GreatlandGold/status/1432222036127006722
Puts it into perspective.
GLA

WSJ - next bit
It took U.K. researchers and government advisers almost a year to plan and gain approval from a U.K. ethics committee and medicines regulators to start the controversial challenge trials for which the Delta strain could eventually be used. The government provided funding; so did the London-based Wellcome Trust, a large healthcare-focused charitable foundation.

The Wellcome Trust and Imperial College London will control the use of the Delta strain, including potentially sharing it with other researchers, Dr. Catchpole said. Meanwhile, he said hVivo and its partners also have a so-called Beta version of the virus, one that originally circulated in South Africa, stored securely in a freezer in case it is needed.

Imperial and hVivo said in May they had signed a £3 million contract, equivalent to around $4.1 million, funded by the Wellcome Trust to manufacture emerging coronavirus variants. It wasn’t clear then which variants researchers could successfully grow in the lab. A Wellcome Trust spokesman declined to comment. An Imperial spokesman said variant production so far hasn’t reached the standards for clinical use, but that work is ongoing.

The challenge trials faced pushback from some U.K. academics and foreign researchers, as well as from some government officials, who considered them unsafe or otherwise unethical, people involved in the process say. Delays have caused friction among partners. hVivo, part of London-listed pharma-services company Open Orphan PLC, ORPH -1.89% had hoped to use the Covid-19 challenge-trial model by now to test antivirals and other products for drug companies, executives have told industry peers. A U.K. government spokesman said the pace of the challenge studies has reflected appropriate caution, and the trials have been safe.

WSJ Part-Extract
With colleagues in the Netherlands, hVivo has coaxed the Delta strain to mature through the seed stage, said Andrew Catchpole, hVivo’s chief scientific officer and a virologist, who oversees the virus manufacturing. The London clinical-research firm is continuing to grow the batch milliliter by milliliter from a specimen taken from an infected human.

There is almost enough volume of the lab-grown virus for initial testing, he said, though the process has been trickier than with other strains.

“Delta has been more difficult. Not all clinical samples grow as readily in cell cultures,” Dr. Catchpole said.

At each stage, researchers screen for mutations and contaminants. The virus is contained and can’t be allowed to evolve differently from what is naturally circulating, he said.

Dr. Catchpole said hVivo hopes to transfer the Delta virus to London in coming weeks to finish it in a second regulated laboratory. If the process goes as planned, Dr. Catchpole said researchers could have half a liter or more produced by November. About a third of that would probably be used up in testing, he said, with the rest ready for trials around year-end.

Update from Simon after market closed.
https://www.investorschronicle.co.uk/ideas/2021/08/23/bargain-shares-on-the-earnings-upgrade/
GLA

Stuart confirmed that the £1.50 is VAT inclusive.

Good interview, company in a great place. Thanks Elric.
BOL

SP benefitting from the IC article which has now been published in today's paper version. Expect rise today and Monday on the back of the article.
GLA

After market closed Simon released a bullish update and raised his target price from 25p to 35p. Expect SP to rise tomorrow.
https://www.investorschronicle.co.uk/ideas/2021/08/19/a-smart-technology-play-offering-material-upside/
GLA

Great RNS today, pleased with the content.
Elric has confirmed that he is interviewing Stuart tomorrow so expect a nice update from him afterwards.
GLA

https://www.investorschronicle.co.uk/ideas/2021/08/16/venture-life-investors-overlook-massive-earnings-upgrades/

After market closed Simon has published a bullish article on Duke which bodes well for tomorrow & beyond.
GLA

After market closed, Simon released a bullish article ahead of their results.
GLA

I would expect Simon to update this week following the results. On 11th June he raised his target price from 25p to 30p with a strong buy recommendation. The results have not disappointed so would expect a bullish article to appear any day now.
GLA

Thanks Wallyj, great notes.
I was particularly interested in 'CF was in Antwerp around a month ago - expansion plans?
Let’s watch this space in Antwerp and Benelux - something positive coming in the next month or two'
He seemed to get quite excited on this one.
GLA

Presentation scheduled for September 6th at 12.30pm.
GLA

Looking forward to Monday, presentation from CF & expecting a RNS with new information.
GLA

Great update Elric, looking forward to seeing the news this month.

https://twitter.com/OpenOrphan/status/1423163876682739713
GLA

https://twitter.com/OpenOrphan/status/1423163876682739713
GLA

Next presentation due on Monday, so news should be coming in the next few days IMHO or he has nothing new to say.
GLA